Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vanguard U.S. Momentum Factor ETF (NY:VFMO)

194.79 -4.03 (-2.03%)
Official Closing Price Updated: 6:30 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vanguard U.S. Momentum Factor ETF

< Previous 1 2 Next >
Sana Biotech Stock Jumps A Whopping 35% After Eric Jackson Calls It ‘Next 100-Bagger Platform’
Via Stocktwits
FDA Approves Alzheimer’s Test Developed By Roche In Collaboration With Eli Lilly
The blood-based test is aimed at aiding the initial assessment for Alzheimer’s disease and other causes of cognitive decline in the primary-care setting in patients aged 55 and older. 
Via Stocktwits
Apollo Global Eyes Spanish Market With Focus On Energy, Data Centers, And Infrastructure: Report
According to a Bloomberg News report, these sectors are where Apollo will be looking for players with the “biggest needs.” 
Via Stocktwits
Topics Government
AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level
Via Stocktwits
Eli Lilly Terminates Study Of Bimagrumab In Obesity
Via Stocktwits
Eli Lilly Announces Plan To Construct New $6.5B Facility In Texas
Via Stocktwits
Scholar Rock In Spotlight After FDA Refuses To Approve Muscular Atrophy Treatment Over Third-Party Manufacturing Facility Issues
Via Stocktwits
KalVista Pharmaceuticals’ Hereditary Angioedema Drug Approved In EU, Switzerland: Retail Sees Stock Rallying To $22 In A Year
Via Stocktwits
Uber Inks Partnership With Flytrex For Drone Delivery In US: Retail Sees Stock ‘Going Higher For Longer’
Via Stocktwits
Roivant Stock Rises After Drug Achieves Goals In Late-Stage Study: Retail Sees Further Rally To $17
Once-daily oral Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all key secondary endpoints in the study,... 
Via Stocktwits
Duolingo Stock Dips After Citigroup Lowers Price Target – Here’s What The Analyst Said About Duocon Event
Citigroup maintained a ‘Buy’ rating and noted that Duolingo's product announcements this year had a lower profile relative to the past. 
Via Stocktwits
Topics Artificial Intelligence
Eli Lilly To Set Up $5B Facility In Virginia – More Details Inside
Via Stocktwits
Ralph Lauren Unveils Three-Year Outlook – Here Are The Key Points
Via Stocktwits
Dave & Buster’s Sees Wall Street Downgrades, Yet Retail Sentiment Red-Hot
UBS said that while Dave & Buster’s was still in the early stages of a turnaround, with macro pressure remaining elevated and visibility limited, an eventual return to consistently positive same-store... 
Via Stocktwits
Caleres Draws ‘Less Risk’ Rating From Telsey, Retail Chatter Surges 700%
Via Stocktwits
Iovance Stock Rises 4% On Health Canada Approval For Cancer Immunotherapy: Retail Thinks ‘Patience Will Pay Off’
Via Stocktwits
Lyft Has A ‘Steady Path Forward’ According To UBS: Retail Thinks Stock Is Undervalued
Via Stocktwits
Ardelyx Stock Soars On Price Target Hikes After Upbeat Q2 Report: Retail Sees More Revisions Coming
Via Stocktwits
Summit Therapeutics Gets A $40 Price Target As Guggenheim Says It Likes Stock At $24, Like It Did At $3
The price target of $40 represents an upside of 70% from the stock’s closing price on Wednesday. 
Via Stocktwits
Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More
While the FDA was originally expected to decide on the company’s application for Pyrukynd in treating thalassemia by September 7, its decision is now expected by December 7. 
Via Stocktwits
Zymeworks Stock Tanks Over 17% After Cancer Drug Candidate Update
The company was testing the drug in an early-stage trial in patients with ovarian cancer and non-small cell lung cancer. 
Via Stocktwits
HC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of Week
The analyst sees Insmed as "poised to join the ranks" of Roche's Genentech and Pfizer's Seagen as companies that have successfully deployed the "pipeline-in-a-pill" strategy. 
Via Stocktwits
Vertex Stock Sinks 12% As Pipeline Setbacks Trigger Wall Street Skepticism: But Retail Sees Opportunity
Via Stocktwits
Oscar Health Now Expects Loss From Operations Of $200M To $300M In 2025: Here’s What Retail Thinks About The Stock Price
Via Stocktwits
Hims & Hers Announces Plans To Expand Into Canada As Novo Nordisk’s Weight Loss Drug Patent Expires
The telehealth company stated that its entry to Canada will come as generic semaglutide hits the market for the first time. 
Via Stocktwits
Topics Intellectual Property
Rhythm Pharma Shares Soar After Experimental Drug Yields Weight Reduction In Brain-Damage Related Obesity
Rhythm now plans to seek input from U.S. and EU regulatory authorities on a late-stage trial design to advance Bivamelagon in acquired hypothalamic obesity. 
Via Stocktwits
Topics Government
KalVista Stock Soars Pre-Market On FDA Approval For Drug In Treating Swelling Disorder: Retail’s Elated
Ekterly is the first and only oral on-demand treatment for hereditary angioedema, KalVista said, setting it apart from other on-demand treatment options approved in the U.S., which require intravenous... 
Via Stocktwits
AstraZeneca In Talks To License Summit Therapeutics’ Experimental Lung Cancer Drug: Report
While the terms of the partnership agreement are still being negotiated, it could include an upfront payment worth several billion dollars and milestone payments, Bloomberg reported, while noting that... 
Via Stocktwits
5 Surprising Vanguard ETFs That Could Beat the Market
Not all Vanguard ETFs are the index funds you're probably familiar with. 
Via The Motley Fool
Topics ETFs
After Beating the S&P 500 in 2024, This Vanguard Growth ETF Is Already Up Over 6% in 2025
Via The Motley Fool
Topics ETFs Stocks
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.